Navigation Links
Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Date:3/26/2008

dication in Japan, sponsored by the Company's partner, Shionogi.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization.
News releases and additional information are available at http://www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
2. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
3. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
4. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
5. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
6. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
7. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
8. AEterna Zentaris Announces Outcome of Managements Strategic Review
9. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
10. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
11. SPO Medical Begins Shipping PulseOx 6000(TM) and PulseOx 6100(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine Inc. ... aware of a fraudulent press release disseminated this morning ... be from Immunovaccine. This press release states that Immunovaccine ... Inc. The press release did not originate from ... contained within the press release. Please note that ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... patients and health care advocates in the United States ... Rare Disease Day is dedicated to elevating public ... special challenges faced by patients with rare diseases and ... to stand alongside patients and caregivers representing the rare ...
(Date:2/26/2015)... VIEW, Calif. , Feb. 26, 2015  23andMe, ... of Kate Black as Privacy Officer and ... federal, and state privacy laws as well as health ... regulatory team, she will be responsible for reviewing, updating ... customers in the U.S. and abroad. She joined the ...
Breaking Biology Technology:Immunovaccine Disclaims Hoax Press Release 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 623andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2
... Smith & Co., Inc.,acted as the exclusive advisor ... d/b/a NJOY, as announced by Charles Botchway, Group,Managing ... Company, Inc. The,transaction was led by Houlihan ... , "We appreciate the ...
... Bionics Inc., "Victhom" (TSX: VHB), today announced the ... www.victhom.com . The Website features a new structure ... divisions; Neurobionix, which is developing an implantable neurostimulation ... developing and manufacturing computerized prostheses for above-knee amputees. ...
... 9 /PRNewswire/ - Sirius Genomics, a developer of ... a collaborative agreement with the United Kingdom Critical ... the continued development of Sirius, pharmacogenomic diagnostic for ... Eli Lilly and Company under the trademark Xigris(R)). ...
Cached Biology Technology:Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc. 2Victhom Announces Launch of Enhanced Company Website 2Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group 2
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62114357 for DISTRIBUTED VOICE ... patent, NXT-ID introduces a new groundbreaking payment method. Payment ... payment account may only be accessed if both the ...
(Date:2/12/2015)... OXFORD, Conn. , Feb. 12, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... it has filed provisional patent 62/113114 for ... MULTIPLE DEVICES. The patent further establishes NXT-ID,s ... to its intellectual property portfolio the ability for multiple ...
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... Cancer is not a static disease but during its ... adapting to new environmental circumstances, protecting against chemotherapy and ... Until now little was known about the mechanisms involved ... a particularly intriguing way in which a tumour that ...
... at the University of California, Davis, have demonstrated that forest ... rocks, boosting the trees, growth and their ability to pull ... dioxide is the most important climate-change gas, the nitrogen in ... in the future, the researchers say. They report their findings ...
... Sept 1, 2011) Lincoln Park Zoo applauds the federal government,s ... chimpanzees living in the United States as an endangered species. ... conservation of the species, which is endangered in the wild. ... Nature, wild chimpanzees are severely endangered and could become extinct ...
Cached Biology News:Why cancer cells change their appearance? 2Bedrock nitrogen may help forests buffer climate change, study finds 2Bedrock nitrogen may help forests buffer climate change, study finds 3Lincoln Park Zoo applauds government decision to consider reclassifying chimpanzees as endangered 2
Agar, 5 lb. Bacteriological.Moisture: < 10%, ash: < 6.5%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
... qualitatively detect EGFR gene ... (FFPE) tissue sections, metaphase ... preparations, using Chromogenic In ... In Situ Hybridization (FISH) ...
Request Info...
Biology Products: